Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

Factors Affecting Shelf Life Several factors can influence the shelf life of compounded semaglutide, including: Quality of Compounding : The specific formulation and compounding practices can vary from pharmacy to pharmacy, potentially affecting the medications stability
Start with protein like eggs, Greek yogurt, or cottage cheese, then layer in fiber from berries or vegetables, and finish with healthy fats such as nuts or seeds to keep energy steady through the morning
This can include consulting with a healthcare provider about any potential allergies or pre-existing conditions that might increase the risk of itching
Telehealth platforms provide quick access to doctors who can evaluate your symptoms and medical history to guide safe medication use